{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:15:30Z","timestamp":1783635330270,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005860","name":"Helsefonden","doi-asserted-by":"publisher","award":["16-B-0171"],"award-info":[{"award-number":["16-B-0171"]}],"id":[{"id":"10.13039\/501100005860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C8162\/A27047"],"award-info":[{"award-number":["C8162\/A27047"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10549-021-06312-6","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T09:03:20Z","timestamp":1625130200000},"page":"551-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Variations in pathways and resource use in follow-up after abnormal mammography screening: a nationwide register-based study"],"prefix":"10.1007","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-0351","authenticated-orcid":false,"given":"Susanne Fogh","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-6504","authenticated-orcid":false,"given":"Berit","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Lernevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-645X","authenticated-orcid":false,"given":"Matejka","family":"Rebolj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-4176","authenticated-orcid":false,"given":"Sisse Helle","family":"Njor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"6312_CR1","unstructured":"International Agency for Research on Cancer. Cancer Today. (2020). https:\/\/gco.iarc.fr\/today\/home. Accessed June 2021"},{"issue":"9855","key":"6312_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(12)61611-0","volume":"380","author":"Screening IUPoBC","year":"2012","unstructured":"Screening IUPoBC (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380(9855):1778\u201386","journal-title":"Lancet"},{"issue":"1","key":"6312_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0969141314563632","volume":"22","author":"SH Njor","year":"2015","unstructured":"Njor SH, Schwartz W, Blichert-Toft M, Lynge E (2015) Decline in breast cancer mortality: how much is attributable to screening? J Med Screen 22(1):20\u201327","journal-title":"J Med Screen"},{"key":"6312_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3322\/caac.21452","volume":"68","author":"CA Doubeni","year":"2018","unstructured":"Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA et al (2018) Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin 68:119","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"6312_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.10453","volume":"94","author":"IA Olivotto","year":"2002","unstructured":"Olivotto IA, Gomi A, Bancej C, Brisson J, Tonita J, Kan L et al (2002) Influence of delay to diagnosis on prognostic indicators of screen-detected breast carcinoma. Cancer 94(8):2143\u20132150","journal-title":"Cancer"},{"key":"6312_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/jnci\/djz137","volume":"112","author":"WE Barlow","year":"2019","unstructured":"Barlow WE, Beaber EF, Geller BM, Kamineni A, Zheng Y, Haas JS et al (2019) Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium. J Natl Cancer Inst 112:238","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"6312_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11606-015-3552-7","volume":"31","author":"ANA Tosteson","year":"2016","unstructured":"Tosteson ANA, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP et al (2016) Variation in screening abnormality rates and follow-up of breast, cervical and colorectal cancer screening within the PROSPR Consortium. J Gen Intern Med 31(4):372\u2013379","journal-title":"J Gen Intern Med"},{"issue":"9","key":"6312_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1002\/cam4.2970","volume":"9","author":"AJ Kumar","year":"2020","unstructured":"Kumar AJ, Banco D, Steinberger EE, Chen J, Weidner R, Makim S et al (2020) Time to diagnostic resolution after an uncertain screening mammogram in an underserved population. Cancer Med 9(9):3252\u20133258","journal-title":"Cancer Med"},{"issue":"12","key":"6312_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1089\/jwh.2015.5661","volume":"25","author":"BA Oppong","year":"2016","unstructured":"Oppong BA, Dash C, Coleman T, Torres T, Adams-Campbell LL (2016) Time to diagnostic evaluation after mammographic screening in an urban setting. J Womens Health (Larchmt) 25(12):1225\u20131230","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"6312_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JOP.2011.000413","volume":"8","author":"ML Quan","year":"2012","unstructured":"Quan ML, Shumak RS, Majpruz V, Holloway CMD, O\u2019Malley FP, Chiarelli AM (2012) Improving work-up of the abnormal mammogram through organized assessment: results from the ontario breast screening program. J Oncol Pract 8(2):107\u2013112","journal-title":"J Oncol Pract"},{"key":"6312_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/CLEP.S99467","volume":"8","author":"EM Mikkelsen","year":"2016","unstructured":"Mikkelsen EM, Njor SH, Vejborg I (2016) Danish quality database for mammography screening. Clin Epidemiol 8:661\u2013666","journal-title":"Clin Epidemiol"},{"key":"6312_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundb\u00f8ll J, Laugesen K, Ehrenstein V et al (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563\u2013591","journal-title":"Clin Epidemiol"},{"key":"6312_CR13","unstructured":"Danish Breast Cancer Cooperative Group (DBCG) (2011) Clinical guidelines 2. Diagnosis [in Danish]"},{"key":"6312_CR14","unstructured":"Vejborg I, Mikkelsen E, Garne JP, Bak M, Lernevall A, Mogensen NB, Schwartz W, Lynge E (2011) Mammography screening in Denmark clinical guidelines. Dan Med Bull 58(6):C4287"},{"key":"6312_CR15","unstructured":"Perry N, Broeders M, de Wolf C, T\u00f6rnberg S, Holland R, von Karsa L et al (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4 edn, p 416"},{"key":"6312_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential(Report). Clin Epidermiol 7:449","journal-title":"Clin Epidermiol"},{"issue":"7_suppl","key":"6312_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1403494810393563","volume":"39","author":"B Bjerregaard","year":"2011","unstructured":"Bjerregaard B, Larsen OB (2011) The Danish Pathology Register. Scand J Public Health. 39(7_suppl):72\u20134","journal-title":"Scand J Public Health."},{"key":"6312_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CLEP.S9908","volume":"2","author":"R Erichsen","year":"2010","unstructured":"Erichsen R, Lash TL, Hamilton-Dutoit S, Bjerregaard B, Vyberg M, Pedersen L (2010) Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2:51\u201356","journal-title":"Clin Epidemiol"},{"issue":"7","key":"6312_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","volume":"39","author":"ML Gjerstorff","year":"2011","unstructured":"Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7):42\u201345","journal-title":"Scand J Public Health"},{"issue":"8","key":"6312_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541\u20139","journal-title":"Eur J Epidemiol"},{"key":"6312_CR21","unstructured":"Netherlands Comprehensive Cancer Organization. National evaluation of breast cancer screening in the Netherlands (2019) https:\/\/www.iknl.nl\/en\/screening. Accessed June 2021"},{"key":"6312_CR22","unstructured":"Screening & Immunisations Team (NHS Digital) & Screening PHE. Breast Screening Programme England, 2018\u201319. (2020) Breast Screening Programme, England 2019-20 - NHS Digital. Accessed June 2021"},{"issue":"1","key":"6312_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/096914130301100107","volume":"11","author":"O Ganry","year":"2004","unstructured":"Ganry O, Peng J, Dubreuil A (2004) Influence of abnormal screens on delays and prognostic indicators of screen-detected breast carcinoma. J Med Screen 11(1):28\u201331","journal-title":"J Med Screen"},{"issue":"3","key":"6312_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1471-6712.2008.00634.x","volume":"23","author":"B Hafslund","year":"2009","unstructured":"Hafslund B, Nortvedt MW (2009) Mammography screening from the perspective of quality of life: a review of the literature. Scand J Car Sci 23(3):539\u2013548","journal-title":"Scand J Car Sci"},{"issue":"9","key":"6312_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1055-9965.EPI-15-0060","volume":"24","author":"A Bolejko","year":"2015","unstructured":"Bolejko A, Hagell P, Wann-Hansson C, Zackrisson S (2015) Prevalence, long-term development, and predictors of psychosocial consequences of false-positive mammography among women attending population-based screening. Cancer Epidemiol Biomark Prev 24(9):1388\u20131397","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"6312_CR26","doi-asserted-by":"publisher","first-page":"e7536","DOI":"10.1136\/bmj.e7536","volume":"345","author":"M Kalager","year":"2012","unstructured":"Kalager M, Tamimi RM, Bretthauer M, Adami H-O (2012) Prognosis in women with interval breast cancer: population based observational cohort study. BMJ Br Med J 345:e7536","journal-title":"BMJ Br Med J"},{"key":"6312_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41523-017-0014-x","volume":"3","author":"N Houssami","year":"2017","unstructured":"Houssami N, Hunter K (2017) The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. NPJ Breast Cancer 3:12","journal-title":"NPJ Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06312-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T06:09:35Z","timestamp":1628662175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06312-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6312"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06312-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>Financial interests<\/i> Matejka Rebolj's employer received a speaker fee on her behalf from Hologic. She has attended meetings with manufacturers of various cervical cancer screening technologies. Susanne Fogh J\u00f8rgensen, Berit Andersen, Anders Lernevall and Sisse Helle Njor reports no financial interests. <i>Non-financial interests<\/i> none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to EU's General Data Protection Regulation (article 30), the project was listed at the record of processing activities for research projects in Central Denmark Region (J. No.: 1-16-02-301-18). According to the Consolidation Act on Research Ethics Review of Health Research Projects, Consolidation Act number 1083 of 15 September 2017 Sect.\u00a014, notification of registry-based studies is only required if the project involves human biological material. Therefore, this study did not need an approval from the Ethics Committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}